Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-25T01:29:13.069Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines

Published online by Cambridge University Press:  01 January 2021

Lisa Cosgrove  and
Emily E. Wheeler
Get access Rights & Permissions [Opens in a new window]

Extract

The profession of medicine is predicated upon an ethical mandate: first do no harm. However, critics charge that the medical profession’s culture and its public health mission are being undermined by the pharmaceutical industry’s wide-ranging influence. In this article, we analyze how drug firms influence psychiatric taxonomy and treatment guidelines such that these resources may serve commercial rather than public health interests. Moving beyond a conflict-ofinterest model, we use the conceptual and normative framework of institutional corruption to examine how organized psychiatry’s dependence on drug firms has distorted science. We suggest that academic-industry relationships have led to the corruption of the evidence base upon which accurate diagnosis and sound treatment depend. We describe the current dependency corruption and argue that transparency alone is not a solution — and sometimes even produces iatrogenic effects. Furthermore, we argue that the corruption of the evidence base for diagnostic and practice guidelines renders obsolete the traditional informed consent process, and we offer suggestions for reforming this process.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 41 , Issue 3 , Fall 2013 , pp. 644 - 653
Copyright
Copyright © American Society of Law, Medicine and Ethics 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association, 2011 Annual Report, 2011, available at <http://www.psychiatry.org/about-apa–psychiatry/annual-reports> (last visited June 7, 2013).+(last+visited+June+7,+2013).>Google Scholar
Lessig, L., Republic, Lost: How Money Corrupts Congress – and a Plan to Stop It (New York: Twelve Books, 2011).Google Scholar
Carlat, D., “Psychiatry's DSM-IV Process: Now a Bar Room Brawl,” June 30, 2009, available at <http://carlatpsychiatry.blogspot.com/2009/06/psychiatrys-dsm-v-process-now-bar-room.html> (last visited June 7, 2013). (last visited June 7, 2013).' href=https://scholar.google.com/scholar?q=Carlat,+D.,+“Psychiatry's+DSM-IV+Process:+Now+a+Bar+Room+Brawl,”+June+30,+2009,+available+at++(last+visited+June+7,+2013).>Google Scholar
Wilson, M., “DSM-III and the Transformation of American Psychiatry: A History,” American Journal of Psychiatry 150, no. 3 (1993): 399–410.Google Scholar
Ronson, J., “Bipolar Kids: Victims of the ‘Madness Industry’?” New Scientist 210, no. 2815 (June 4, 2011): 44–47.CrossRefGoogle Scholar
See Lessig, , see supra note 2.Google Scholar
Id.Google Scholar
Pollack, G. H., “Report of the Treasurer,” American Journal of Psychiatry 138, no. 10 (1981): 1415–1417.CrossRefGoogle Scholar
American Psychiatric Association, 2008 Annual Report, 2008, available at <http://www.psychiatry.org/about-apa–psychiatry/annual-reports> (last visited June 7, 2013).+(last+visited+June+7,+2013).>Google Scholar
American Psychiatric Association, “Report of the Secretary-Treasurer (Item 2009A #1.C),” May 15–17, 2009.Google Scholar
Frances, A., “A Warning Sign on the Road to DSM-V: Beware of Its Unintended Consequences,” Psychiatric Times, June 26, 2009, available at <http://www.psychiatrictimes.com/display/article/10168/1425378> (membership required to view article).+(membership+required+to+view+article).>Google Scholar
Moynihan, R. Heath, I. Henry, D., “Selling Sickness: The Pharmaceutical Industry and Disease Mongering,” BMJ 324, no. 7342 (2002): 886–891.CrossRefGoogle Scholar
Frances, A., “Opening Pandora's Box: The 19 Worst Suggestions for DSM5,” Psychiatric Times, February 11, 2010, available at <http://www.psychiatrictimes.com/home/content/article/10168/1522341?pageNumber=2&verify=0) (membership required to view article).Google Scholar
Angell, M., The Truth About the Drug Companies: How They Deceive Us and What To Do About It (New York: Crown Publishing Group/Random House, 2004).Google Scholar
Endicott, J. Amsterdam, J. Eriksson, E. Frank, E. Freeman, E. Hirschfeld, R. Ling, F. Parry, B. Pearlstein, T. Rosenbaum, J. Rubinow, D. Schmidt, P. Severino, S. Steiner, M. Stewart, D. E. Thys-Jacobs, S., “Is Premenstrual Dysphoric Disorder a Distinct Clinical Entity?” Journal of Women's Health & Gender-Based Medicine 8, no. 5 (1999): 663–679.CrossRefGoogle Scholar
Axelson, D. A. Bimaher, B. Findling, R. L. Fristad, M. A. Kowatch, R. A. Youngstrom, E. A. Arnold, E. L. Goldstein, B. I. Goldstein, T. R. Chang, K. D. Delbello, M. P. Ryan, N. D. Diler, R. S., “Concerns Regarding the Inclusion of Temper Dysregulation Disorder with Dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,” Journal of Clinical Psychiatry 72, no. 9 (2011): 1257–1262; Robbins, B. D. Higgins, M. Fisher, M. Over, K., “Conflicts of Interest in Research on Antipsychotic Treatment in Pediatric Bipolar Disorder, Temper Dysregulation Disorder, and Attenuated Psychotic Symptoms Syndrome: Exploring the Unholy Alliance Between Big Pharma and Psychiatry,” Journal of Psychological Issues in Organizational Culture 1, no. 4 (2011): 32–49.CrossRefGoogle Scholar
Batstra, L. Frances, A., “Diagnostic Inflation: Causes and a Suggested Cure,” Journal of Nervous and Mental Disease 200, no. 6 (2012): 474–479.CrossRefGoogle Scholar
Pies, R. Zisook, S., “DSM Criteria Won't ‘Medicalize’ Grief, If Clinicians Understand Grief,” Psychiatric Times, February 16, 2010, available at <http://www.psychiatrictimes.com/display/article/10168/1523978> (membership required to view article). (membership required to view article).' href=https://scholar.google.com/scholar?q=Pies,+R.+Zisook,+S.,+“DSM+Criteria+Won't+‘Medicalize’+Grief,+If+Clinicians+Understand+Grief,”+Psychiatric+Times,+February+16,+2010,+available+at++(membership+required+to+view+article).>Google Scholar
See Frances, , supra note 13, at 2.Google Scholar
American Psychiatric Association, “Board of Trustee Principles,” (2012) available at <http://www.dsm5.org/about/Pages/BoardofTrusteePrinciples.aspx> (last visited June 7, 2013).+(last+visited+June+7,+2013).>Google Scholar
Cosgrove, L. Krimsky, S., “A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists,” PLoS Medicine 9, no. 3 (2012): e1001190.CrossRefGoogle Scholar
Institute of Medicine, Clinical Practice Guidelines: Directions for a New Program, Field, M. J. Lohr, K. N., eds. (Washington, D.C.: National Academy Press, 1990).CrossRefGoogle Scholar
Shaneyfelt, T. M. Centor, R.M., “Reassessment of Clinical Practice Guidelines: Go Gently into that Good Night,” JAMA 301, no. 8 (2009): 868–869.CrossRefGoogle Scholar
Krimsky, S., “Combating the Funding Effect in Science: What's Beyond Transparency?” Stanford Law Policy Review XXI, no. 1 (2010): 101–123.Google Scholar
Bekelman, J. Li, Y. Gross, C., “Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review,” JAMA 289, no. 4 (2003): 454–465; Stelfox, H. Chua, G. O'Rourke, K. Detsky, A., “Conflict of Interest in the Debate Over Calcium-Channel Antagonists,” New England Journal of Medicine 338, no. 2 (1998): 101–106; Kjaergard, L. Als-Nielsen, B., “Association between Competing Interests and Authors’ Conclusions: Epidemiological Study of Randomised Clinical Trials Published in the BMJ,” BMJ 325, no. 7358 (2002): 249. Because pharmaceutical firms can affect study conclusions by funding and directing the research, several authors have called for independent clinical trials to test drugs for obtaining authorization to market drugs and to evaluate drugs once on the market. See Rodwin, M., “Five UnEasy Pieces to Pharmaceutical Policy Reform,” Journal of Law, Medicine and Ethics 41, no. 3 (2013): 581–589; Light, D. W. Lexchin, J. Darrow, J., “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” Journal of Law, Medicine and Ethics 41, no. 3 (2013): 590–600.Google Scholar
Quanstrum, K. H. Hayward, R. A., “Lessons from the Mammography Wars,” New England Journal of Medicine 363, no. 11 (2010): 1076–1079.CrossRefGoogle Scholar
Institute of Medicine (IOM), Clinical Practice Guidelines We Can Trust (Washington, D.C.: National Academies Press, 2011).Google Scholar
Mehlman, M., “Medical Practice Guidelines as Malpractice Safe Harbors: Illusion or Deceit?” Journal of Law, Medicine & Ethics 40, no. 2 (2012): 286–300.CrossRefGoogle Scholar
Elliott, C., “Industry-Funded Bioethics and the Limits of Disclosure,” in Arnold, D. G., ed., Ethics and Business of Biomedicine (Cambridge University Press, 2009): 150–168, at 161.Google Scholar
See Lessig, , supra note 2.Google Scholar
Id.; Rodwin, M. A., “Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform,” Journal of Law, Medicine & Ethics 40, no. 2 (2012): 511–522.CrossRefGoogle Scholar
Elias, M., “Conflicts of Interest Bedevil Psychiatric Drug Research,” USA Today, June 3, 2009, available at <http://usatoday30.usatoday.com/news/health/2009-06-02-psychiatry-drugs-conflicts_N.htm> (last visited June 7, 2013).+(last+visited+June+7,+2013).>Google Scholar
Avorn, J. Chen, M. Hartley, R., “Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians,” American Journal of Medicine 73, no. 1 (1982): 4–8; Orlowski, J. Wateska, L., “The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns,” Chest 102, no. 1 (1992): 270–273.Google Scholar
Dana, J. Loewenstein, G., “A Social Science Perspective on Gifts to Physicians From Industry,” JAMA 290, no. 2 (2003): 252–255.CrossRefGoogle Scholar
Lexchin, J. O'Donovan, O., “Prohibiting or ‘Managing’ Conflict of Interest? A Review of Policies and Procedures in Three European Drug Regulation Agencies,” Social Science & Medicine 70, no. 5 (2010): 643–647.CrossRefGoogle Scholar
Yank, V. Rennie, D. Bero, L., “Financial Ties and Concordance between Results and Conclusions in Meta-Analyses: Retrospective Cohort,” BMJ 335, no. 7631 (2007): 1202–1205.CrossRefGoogle Scholar
Cosgrove, L. Shaughnessy, A. F. Wheeler, E. E. Austad, K. E. Kirsch, I. Bursztajn, H. J., “The American Psychiatric Association's Guideline for Major Depressive Disorder: A Commentary,” Psychotherapy and Psychosomatics 81, no. 3 (2012): 186–188.CrossRefGoogle Scholar
Kirsch, I. Deacon, B. J. Huedo-Medina, T. B. Scoboria, A. Moore, T. J. Johnson, B. T., “Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration,” PLoS Medicine 5, no. 2 (2008): E45; Fournier, J. C. DeRubeis, R. J. Hollon, S. D. Dimidjian, S. Amsterdam, J. D. Shelton, R. C. Fawcett, J., “Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-Analysis,” JAMA 303, no. 1 (2010): 47–53.Google Scholar
See Kirsch, Deacon, Huedo-Medina, Scoboria, Moore, Johnson, , supra note 38, at 260.Google Scholar
See Fournier, DeRubeis, Hollon, Dimidjian, Amsterdam, Shelton, Fawcett, , supra note 38, at 51–52.Google Scholar
American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder (2010), at 31.Google Scholar
For insights on the role of pharma influencing key opinion leaders see, Sismondo, S., “Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 635–643.CrossRefGoogle Scholar
National Institute for Health and Clinical Excellence, “Depression: The Treatment and Management of Depression in Adults,” NICE Clinical Guideline no. 90 (2009), London, U.K.Google Scholar
Van Weel-Baumgarten, E. M. Van Gelderen, M. G. Grundmeijer, H. G. L. M. Licht-Strunk, E. Van Marwijk, H. W. J. Van Rijswijk, H. C. A. M. Tjaden, B. R. Verduijn, M. Wiersma, T. Burgers, J. S. Van Avendonk, M. J. P. Van der Weele, G. M., “NHG Standaard Depressie (Tweede Herziening),” Huisarts en Wetenschap 55, no. 6 (2012): 252–259.Google Scholar
International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest,” April, 2010, available at <http://www.icmje.org/urm_full.pdf> (last visited June 7, 2013).+(last+visited+June+7,+2013).>Google Scholar
Brandeis, L., “What Publicity Can Do,” Harper's Weekly 58, December 20, 1913, at 10–13.Google Scholar
See Elliott, , supra note 29; the PLoS Medicine Editors, “Does Conflict of Interest Disclosure Worsen Bias?” PLoS Medicine 9, no. 4 (2012): E1001210.Google Scholar
See Krimsky, , supra note 24, at 108.Google Scholar
Brauser, D., “Psychiatrists Top List of Big Pharma Payments Again,” Medscape, May 14, 2013, available at <http://www.medscape.com/viewarticle/780835> (membership required to view article).+(membership+required+to+view+article).>Google Scholar
See PLoS Medicine Editors, supra note 47; Cain, D. M. Loewenstein, G. Moore, D. A., “When Sunlight Fails to Disinfect: Understanding the Perverse Effects of Disclosing Conflicts of Interest,” Journal of Consumer Research 37, no. 5 (2011): 836–857; Loewenstein, G. Sah, S. Cain, D. M., “The Unintended Consequences of Conflicts of Interest Disclosure,” JAMA 307, no. 7 (2012): 669–670; Sah, S. Loewenstein, G. Cain, D. M., “The Burden of Disclosure: Increased Compliance with Distrusted Advice,” Journal of Personality and Social Psychology 104, no. 2 (2013): 289–304. For discussions of the limitations of disclosures, see in this issue of JLME 41, no. 3 (2013): Sismondo, , supra note 42; Feldman, Y. Gauthier, R. Schuller, T., “Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law,” 620–628; and Brown, A., “Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation,” at 611–619.Google Scholar
See Dana, Loewenstein, , supra note 34; see PLoS Medicine Editors, supra note 47.Google Scholar
Ioannidis, J. P. A. Tatsioni, A. Karassa, F. B., “Who Is Afraid of Reviewers' Comments? Or Why Anything Can Be Published and Anything Can Be Cited,” European Journal of Clinical Investigation 40, no. 4 (2010): 285–287; Pitrou, I. Boutron, I. Ahmed, N. Ravaud, P., “Reporting of Safety Results in Published Reports of Randomized Controlled Trials,” Archives of Internal Medicine 169, no. 19 (2009): 1756–1761.Google Scholar
See Lessig, , supra note 2.Google Scholar
Gopal, A. A. Cosgrove, L. Shuv-Ami, I. Wheeler, E. E. Yerganian, M. J. Bursztajn, H. J., “Dynamic Informed Consent Processes Vital for Treatment with Antidepressants,” International Journal of Law and Psychiatry 35, no. 5–6 (2012): 392–397.CrossRefGoogle Scholar
Id.Google Scholar
Bluhm, R., “Evidence-Based Medicine and Patient Autonomy,” International Journal of Feminist Approaches to Bioethics 2, no. 2 (2009): 134–151.CrossRefGoogle Scholar
Light, D., “Bearing the Risks of Prescription Drugs,” in Light, D., ed., The Risks of Prescription Drugs (New York: Columbia University Press): at 1–39.Google Scholar
Gagnon, M.-A., “Corporate Influence Over Clinical Research: Considering the Alternatives,” Prescrire 32, no. 342 (2012): 311–314.Google Scholar
Rodwin, M. A., “Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal,” Journal of Law, Medicine & Ethics 38, no. 4 (2010): 807–815; Brodkey, A., “The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem,” Academic Psychiatry 29, no. 2 (2005): 222–229.CrossRefGoogle Scholar
Bursztajn, H. J. Feinbloom, R. I. Hamm, R. M., Medical Choices, Medical Chances: How Patients, Families, and Physicians Can Cope with Uncertainty (New York/London: Routledge, 1990).Google Scholar